Long-term efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer: Results of a 2-year follow-up of ENGOT-OV60/GOG-3052/RAMP 201.

Grisham RN, Van Nieuwenhuysen E, Santin AD, D'Hondt V, Thaker PH, Clamp AR, Moore KN, Aghajanian C, Oaknin A, O'Malley DM, Monk BJ, Colombo N, Prendergast EN, Ring KL, Ray-Coquard I, Rose PG, Gourley C, Holloway RW, Chon HS, Van Gorp T, Youssoufian H, Salinas E, Lustgarten S, Banerjee SN

Open source

DOI: 10.1016/j.ygyno.2026.09.003
Published: 2026 Sep 16
Container: Gynecologic oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ygyno.2026.09.003,
  title = {Long-term efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer: Results of a 2-year follow-up of ENGOT-OV60/GOG-3052/RAMP 201.},
  author = {Grisham RN and Van Nieuwenhuysen E and Santin AD and D'Hondt V and Thaker PH and Clamp AR and Moore KN and Aghajanian C and Oaknin A and O'Malley DM and Monk BJ and Colombo N and Prendergast EN and Ring KL and Ray-Coquard I and Rose PG and Gourley C and Holloway RW and Chon HS and Van Gorp T and Youssoufian H and Salinas E and Lustgarten S and Banerjee SN},
  year = {2026},
  journal = {Gynecologic oncology},
  doi = {10.1016/j.ygyno.2026.09.003},
  url = {https://doi.org/10.1016/j.ygyno.2026.09.003}
}

RIS

TY  - JOUR
TI  - Long-term efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer: Results of a 2-year follow-up of ENGOT-OV60/GOG-3052/RAMP 201.
AU  - Grisham RN
AU  - Van Nieuwenhuysen E
AU  - Santin AD
AU  - D'Hondt V
AU  - Thaker PH
AU  - Clamp AR
AU  - Moore KN
AU  - Aghajanian C
AU  - Oaknin A
AU  - O'Malley DM
AU  - Monk BJ
AU  - Colombo N
AU  - Prendergast EN
AU  - Ring KL
AU  - Ray-Coquard I
AU  - Rose PG
AU  - Gourley C
AU  - Holloway RW
AU  - Chon HS
AU  - Van Gorp T
AU  - Youssoufian H
AU  - Salinas E
AU  - Lustgarten S
AU  - Banerjee SN
PY  - 2026
JO  - Gynecologic oncology
DO  - 10.1016/j.ygyno.2026.09.003
UR  - https://doi.org/10.1016/j.ygyno.2026.09.003
ER  -

APA

RN, G., E, V. N., AD, S., V, D., PH, T., AR, C., KN, M., C, A., A, O., DM, O., BJ, M., N, C., EN, P., KL, R., I, R., PG, R., C, G., RW, H., HS, C., T, V. G., H, Y., E, S., S, L., & SN, B. (2026). Long-term efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer: Results of a 2-year follow-up of ENGOT-OV60/GOG-3052/RAMP 201.. Gynecologic oncology. https://doi.org/10.1016/j.ygyno.2026.09.003

Source records

pubmed · retrieved 2026-09-25T16:36:20.631Z